This site is intended for healthcare professionals outside the US.

Go beyond angiogenesis

Target aRCC with the triple antitumor action of AFINITOR1-3

aRCC, advanced renal cell carcinoma; MOA, mechanism of action; mTOR, mammalian target of rapamycin.
  1. AFINITOR [summary of product characteristics]. Novartis Pharma AG; 2017.
  2. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol. 2009;2:45.
  3. Dancey JE. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs. 2005;14(3):313-328.